[Experience with non-Hodgkin's lymphoma].
High-dose chemotherapy with autologous bone-marrow transplantation is active in non-Hodgkin lymphoma patients. The results of randomized trials in the setting of consolidation of first complete remission are not in favor of use of high-dose chemotherapy. However preliminary results of pilot studies are in favor of this treatment in reponder patients. The results of the PARMA protocol will help to answer the question.
Biron
P
P
Département de cancérologie médicale, centre Léon-Bérard, Lyon, France.
Droz
J P
JP
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D012042:Registries; D016879:Salvage Therapy; D015996:Survival Rate
Expérience dans les lymphomes non hodgkiniens.